Drug Trial Radar · NCT04594369
A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis
Last checked: Nov 19, 2026Latest source record: Dec 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,767
Actual
Start
Dec 1, 2020
Primary completion
Oct 28, 2024
Study completion Oct 28, 2024
Sponsor
- Lead sponsor
- Insmed IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- Oct 20, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the effect of brensocatib at 10 mg and 25 mg compared with placebo on the rate of pulmonary exacerbations (PEs) over the 52-week treatment period.
Conditions
- Non-Cystic Fibrosis Bronchiectasis
Interventions
Brensocatib 10 mgDrug
Oral tablet.
Brensocatib 25 mgDrug
Oral tablet.
PlaceboDrug
Brensocatib-matching oral tablet.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Rate of Pulmonary Exacerbations (PEs)Time frame: Up to Week 52
Locations
373 sites in 36 countries. Site status is shown where the registry gives one.
USA013
Birmingham, Alabama
USA080
Conway, Arkansas
USA044
Little Rock, Arkansas
USA104
Fresno, California
USA055
Los Angeles, California
USA029
Newport Beach, California
USA102
Northridge, California
USA022
Palm Springs, California
USA024
Sacramento, California
USA035
San Diego, California
USA078
Santa Barbara, California
USA027
Ventura, California
USA075
Denver, Colorado
USA017
Farmington, Connecticut
USA001
Washington D.C., District of Columbia
USA015
Clearwater, Florida
USA076
Gainesville, Florida
USA082
Jacksonville, Florida
USA039
Kissimmee, Florida
USA072
Leesburg, Florida
USA037
Miami, Florida
USA019
Miami Lakes, Florida
USA049
Naples, Florida
USA052
Orlando, Florida
USA103
Plantation, Florida
USA084
Sarasota, Florida
USA089
St. Petersburg, Florida
USA074
St. Petersburg, Florida
USA120
Tampa, Florida
USA012
Atlanta, Georgia
USA053
Augusta, Georgia
USA073
Chicago, Illinois
USA061
Maywood, Illinois
USA115
Hammond, Indiana
USA063
Iowa City, Iowa
USA031
Kansas City, Kansas
USA020
New Orleans, Louisiana
USA051
New Orleans, Louisiana
USA003
Baltimore, Maryland
USA079
Boston, Massachusetts
Showing 40 of 373 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.